Build status - In Progress

Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors

Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors
Recruiting
18 years - 99 years
All
Phase 1
3 participants needed
1 Location

Brief description of study

study of surufatinib in combination with tislelizumab will evaluate the safety, and tolerability in patients with advanced solid tumors.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: colorectal cancer,neuroendocrine tumors,small-cell lung cancer,gastric cancer,or soft tissue sarcoma,colorectal cancer,neuroendocrine tumors, small-cell lung cancer, gastric cancer, or soft tissue sarcoma
  • Age: 18 years - 99 years
  • Gender: All

Male and Female Over 18 Years of age

Updated on 04 Aug 2024. Study ID: 848814

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center